Earnings call Kuros Biosciences posted FY25 revenue of $146.1M (+72% YoY), adjusted EBITDA of $19.6M (13.4% margin), and first-ever net profit of $2.6M, exceeding guidance. Management guides for at ...
Confusion and missing financial information from Town Hall plague Wilton's Board of Finance meeting. Questions remain unanswered, causing member frustration.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results